Levetiracetam treatment of idiopathic generalised epilepsy

Gregory L. Krauss, Tim Betts, Bassel Abou-Khalil, Gregory Bergey, Helen Yarrow, Akemi Miller

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


Levetiracetam (LEV) is effective for treating localisation-related epilepsy, but it is uncertain whether it is effective for treating idiopathic generalised epilepsy. We compared 12-week baseline and LEV treatment periods for patients with generalised seizure types - myoclonic, tonic-clonic and absence seizures - who had failed other anticonvulsants. The majority of 55 patients (76%) had >50% seizure reduction with LEV therapy, 40% became seizure-free; 15% discontinued LEV due to adverse events, mostly sedation. This is preliminary evidence that LEV is effective for treating idiopathic generalised epilepsy.

Original languageEnglish (US)
Pages (from-to)617-620
Number of pages4
Issue number8
StatePublished - Dec 2003


  • Generalised epilepsy
  • Levetiracetam
  • Seizures

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Levetiracetam treatment of idiopathic generalised epilepsy'. Together they form a unique fingerprint.

Cite this